Introduction Of Immune Modulators To Treat Eczema

17 Aug 2017 11:49

Back to list of posts


Pharmaceutical companies are offering new drugs referred to as immune modulators for the treatment of skin diseases such as eczema. Eczema is a chronic skin condition caused by the lack of skin proteins that results in inflammation and irritation in the skin. These drugs are used to externally treat the skin without changing the immune system of the body. In addition, unlike topical steroids, these new medications do not cause thinning of the skin and breaking of superficial blood vessels. Tacrolimus (Protopic) and Pimecrolimus (Elidel) are major drugs available for the treatment of eczema.


The Business Research Company expects the global dermatology drugs market to grow from $31 billion in 2016 to $37 billion in 2020 at a compound annual growth rate (CAGR) of 5.2%. North America was the largest region in the dermatology drugs market in 2016, accounting for $9 billion or 31.5% market share. This can be attributed to large number of affluent patients and generous reimbursement within the US pharma market.

Purchase the report at

The chart below shows the year-on-year growth of the global dermatology drugs market during 2016-2020


According to The Business Research Company’s Healthcare and Biotechnology Consultant, Ravikiran Drug manufacturing companies are using genome testing to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs.

Request a sample of the report at

Johnson & Johnson (J&J) was the largest competitor in the dermatology drugs market in 2016 with revenues of $3.9 billion for the financial year 2016. Johnson & Johnson aims to grow its geographic footprint and increase investments in emerging markets and developed markets such as Japan. In 2016, the company spent $9.1 billion in R&D. With prioritized investments in internal R&D, strategic licensing arrangements, partnerships and select acquisitions, the company intends to build a robust product pipeline for the long-term. In July 2016, J&J acquired a Japanese beauty brand Dr. Ci:Labo to strengthen its skin care business.
The dermatology drugs market includes medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

Dermatology drugs used to treat acne include local anesthetics, cleansers, anti-inflammatory agents, anti-infectives, emollients, and astringents. These drugs are available for both topical (external) use and internal use. These drugs can be sold as over-the-counter (OTC) as well as prescription drugs. Major OTC dermatological drugs include Differin, Lamisil, Monistat, and Abreva. Some of the major dermatology prescription drugs include Clobetasol propionate, Flucinonide, Baxdela, Siliq, Rhofade.

Dermatology Drugs Market Global Report 2017 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office the price is $6000 and $8000 if you wish to use across a multinational company.

About The Business Research Company

Visit, mail ofni.crbt|ofni#ofni.crbt|ofni or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.

The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.

It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.

The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations.

Comments: 0

Add a New Comment

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License